Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors
Status:
Recruiting
Trial end date:
2021-12-10
Target enrollment:
Participant gender:
Summary
This is a single center, single arm, open-label and phase I clinical study. The standard 3 +
3 group design was performed. Patients were enrolled by the design of phase I study standard.
Sintilimab was divided into three dose levels: 1 mg / kg, 3 mg / kg, and 10 mg / kg. Dose
escalation was carried out from the first level of sintilimab. The study is to evaluate the
safety, including dose limited toxicity (DLT) in the treatment of advanced, recurrent, and
refractory childhood cancer.